SLU-PP-332
Novel ERR agonist studied in preclinical metabolic research.
Research Areas
Scientific Background
SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ). Preclinical research has examined its potential to activate metabolic gene programs.
Deep Dive: How It Works
ERRα is a master regulator of energy metabolism genes. When SLU-PP-332 activates it: (1) MITOCHONDRIAL BIOGENESIS: Upregulates PGC-1α and downstream mitochondrial genes, increasing the number and efficiency of mitochondria in muscle cells; (2) FIBER TYPE SWITCHING: Promotes conversion of Type IIx (fast-twitch, fatigable) muscle fibers to Type I and Type IIa (slow-twitch, fatigue-resistant) fibers — the same adaptation that occurs with endurance training; (3) FATTY ACID OXIDATION: Activates genes for β-oxidation, shifting energy substrate preference from glucose to fatty acids; (4) GENE EXPRESSION: Mouse studies show SLU-PP-332 activates >100 exercise-responsive genes in skeletal muscle without actual physical activity. This makes it an 'exercise mimetic' — it triggers exercise adaptations at the genetic level. Current limitations: The original SLU-PP-332 does NOT cross the blood-brain barrier. Newer analogs (BE5112, BE5049) are being developed with improved BBB permeability for potential neurodegenerative applications.
Key Insight
SLU-PP-332 represents a paradigm shift — it's the first successful agonist of ERRα, a receptor once considered impossible to drug. Its potential extends far beyond 'exercise in a pill' — muscle atrophy from aging, cancer cachexia, and GLP-1 medication side effects are all active research areas. But it is VERY early-stage — no human trials exist yet.
Optimization & Cofactors
Published research on compounds that support this peptide's mechanisms
Cofactor information is compiled from published nutritional and biochemical research. This is educational content, not supplementation advice. Consult a qualified healthcare provider.
Creatine Monohydrate
5g daily with any mealSupports muscle energy enhanced by ERRα activation
Most-studied ergogenic supplement; may complement ERRα mitochondrial biogenesis
CoQ10 (Ubiquinol)
100-200mg with fatty mealNew mitochondria from ERRα need CoQ10 for electron transport
More mitochondria need more electron carriers to function
Protein (Leucine-Rich)
1.6-2.2g/kg/day distributedERRα promotes oxidative muscle fibers — adequate protein supports synthesis
ERRα favors Type I fiber properties — protein prevents catabolism
Iron
ERRα upregulates iron-sulfur cluster enzymes in mitochondria
Check ferritin levels; iron-sulfur clusters essential for expanded mitochondrial function
Compatibility & Stacking Guide
Research on combining peptides based on published mechanisms
Compatibility information is based on published mechanisms of action. No clinical trials have validated most combinations in humans. This is educational content only.
Compatible Compounds (Research-Based)
May counteract GLP-1-associated muscle loss — complementary targets
SLU-PP-332 creates new mitochondria; SS-31 maintains existing — quantity + quality
More mitochondria = more NAD+ demand for electron transport
Timing Guide from Published Research
VERY early-stage — no human dosing protocols exist. Published mouse studies used daily oral administration. No established clinical timing data.
Published Clinical Study Protocols
Data from peer-reviewed publications and registered clinical trials
These protocols are cited from published research for educational purposes only. They do not constitute recommendations. All research must be conducted under appropriate institutional oversight.
ERR Agonist Endurance Enhancement (Preclinical)
Billon et al., Washington University in St. Louis, 2023-2024
Daily administration in murine models with treadmill-based endurance testing over several weeks
Significantly enhanced treadmill running endurance, increased fatigue-resistant muscle fibers, and activated exercise-responsive gene programs without actual exercise.
Optimized ERR Agonists (BE5112/BE5049)
Bhatt et al., PMC, 2025-2026
Structure-activity relationship optimization using functional assays and molecular docking
BE5112 and BE5049 demonstrated superior metabolic stability and more robust target-gene activation compared to SLU-PP-332.
Synergy & Cofactor Research
How this compound interacts with other molecules in research
Exercise Mimetic + Actual Exercise
SLU-PP-332 activates exercise-responsive genes, but actual physical exercise also provides mechanical loading, cardiovascular conditioning, and neurological benefits that a pill cannot replicate.
ERR agonism provides the metabolic gene activation component of exercise adaptation. Actual exercise adds mechanical stress (bone/tendon strengthening), cardiovascular conditioning, and neuroplasticity that require physical stimulus.
GLP-1 Weight Loss Muscle Preservation
GLP-1 medications (semaglutide, tirzepatide) can cause significant muscle loss along with fat loss. ERR agonists are being explored as potential countermeasures to preserve muscle during metabolic weight loss.
GLP-1 agonists reduce caloric intake, which can lead to muscle catabolism. ERR agonism promotes mitochondrial biogenesis and fatigue-resistant fiber maintenance, potentially counteracting muscle loss during caloric restriction.
Purity & Provenance
Why quality matters for research validity
SLU-PP-332 is a small molecule (not a peptide) ERRα agonist. As research-stage with no clinical trials, quality standards are not established. Research-grade material should have ≥95% chemical purity verified by NMR and mass spectrometry.
Areas of Investigation
Laboratory Information
Technical specifications for research settings
This compound is intended for qualified scientific research only. Not for human or veterinary use. Not for diagnostic or therapeutic applications. Researchers must comply with all applicable regulations in their jurisdiction.
Store at -20°C. Protect from light and moisture.
Powder
Research grade
Experimental compound. No human research data available.
Deepen Your Research
Published literature and clinical trial registries
Published Literature
Published research is limited to preclinical animal studies. No human clinical trials have been conducted.
Regulatory Classification
SLU-PP-332 is an early-stage research compound with no human studies. Preclinical data only. For qualified research purposes only.
Important Research Notice
This information is compiled from scientific literature for educational purposes only. This website does not sell, distribute, or recommend any compounds for human use. All compounds discussed are for qualified research purposes only.